1. Performance comparison of aspirin assay between Anysis and VerifyNow: Assessment of therapeutic platelet inhibition in patients with cardiac diseases
- Author
-
SeonYoung Kim, Jinxiang Piao, Chaeyoung Yoo, Sehyun Shin, Youn-Wha Whang, and Cheol Ung Choi
- Subjects
Blood Platelets ,030213 general clinical medicine ,medicine.medical_specialty ,Heart Diseases ,Platelet Aggregation ,Platelet Function Tests ,VerifyNow ,Physiology ,Anysis-200 analyzer ,030204 cardiovascular system & hematology ,Platelet inhibition ,03 medical and health sciences ,0302 clinical medicine ,Physiology (medical) ,Internal medicine ,Humans ,Medicine ,Platelet ,In patient ,Abnormal Platelet ,Aspirin ,business.industry ,Area under the curve ,Hematology ,Blood flow ,Performance comparison ,Cardiology ,Platelet function ,Cardiology and Cardiovascular Medicine ,business ,Platelet Aggregation Inhibitors ,Research Article ,medicine.drug - Abstract
BACKGROUND: Assessment of platelet inhibition for aspirin therapy is important to manage patients who are at potential risk of developing thrombotic and hemorrhagic complications. OBJECTIVE: This study aimed to evaluate a new platelet assay (Anysis-aspirin), compare it with VerifyNow-aspirin in patients with cardiac diseases, and analyze the aspirin resistance rates between the two devices. METHODS: Citrated blood samples were collected from patients with cardiac diseases referred for the aspirin response test. In the Anysis assay, a test result was provided with a blood flow migration distance (MD) until blood flow stoppage, which was comparable to aspirin reaction units (ARUs) obtained using VerifyNow. The measurements were simultaneously conducted using the two devices and compared. RESULTS: The MD without and with aspirin use was 160±33 and 254±23 mm, respectively (p
- Published
- 2021